EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective

Timofey Lebedev iD, Rubina Kousar, Bbumba Patrick iD, Muhammad Usama, Meng-Kuei Lee, Ming Tan iD, Xing-Guo Li

Cells · 2023

DOI: 10.3390/cells12060952 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Timofey Lebedev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Cell Biology, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Neoplasms, Transcription Factors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Andrew McDonough B+ (Be Positive) Foundation’s Childhood Cancer Research Award, the Children’s Cancer Research Fund’s Emerging Scientist Award, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles’ heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTranscription FactorsHumansDNA-Binding ProteinsEpigenesis, GeneticNuclear ProteinsTumor Microenvironment

Stichwörter der Autor:innen

ARID1Acancer immunotherapychromatin remodelingmetabolism

Substanzen

ARID1A protein, humanDNA-Binding ProteinsNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Cancer Cell Biology, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
  • Graduate Institute of Biomedical Sciences, China Medical University, Taichung 110122, Taiwan.
  • Research Center for Cancer Biology, China Medical University, Taichung 110122, Taiwan.
  • Institute of Biochemistry and Molecular Biology, College of Life Sciences, China Medical University, Taichung 110122, Taiwan.

ORCID-Profile: Timofey Lebedev, Bbumba Patrick, Ming Tan

Förderung

  • the Andrew McDonough B+ (Be Positive) Foundation’s Childhood Cancer Research Award
  • the Children’s Cancer Research Fund’s Emerging Scientist Award
  • National Science and Technology Council
  • China Medical University
  • Bear Necessities Pediatric Cancer Foundation

Zitieren

APA

Lebedev, T., Kousar, R., Patrick, B., Usama, M., Lee, M. K., Tan, M., & Li, X. G. (2023). Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective. Cells. https://doi.org/10.3390/cells12060952

Vancouver

Lebedev T, Kousar R, Patrick B, Usama M, Lee MK, Tan M, et al. Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective. Cells. 2023. doi:10.3390/cells12060952

BibTeX
@article{Lebedev2023,
  author = {Lebedev, Timofey and Kousar, Rubina and Patrick, Bbumba and Usama, Muhammad and Lee, Meng-Kuei and Tan, Ming and Li, Xing-Guo},
  title = {Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12060952}
}
Kostenlos starten →